<?xml version="1.0" encoding="UTF-8"?>
<results title="country">
 <result pre="COVID-19 laboratory confirmed cases is ~6.9% ranging from ~0.1% in" exact="Singapore" post="to ~16.3% in Belgium [4]. Whilst it is difficult"/>
 <result pre="is ~6.9% ranging from ~0.1% in Singapore to ~16.3% in" exact="Belgium" post="[4]. Whilst it is difficult to compare case fatality"/>
 <result pre="systems within each country. Clinical characteristics of SARS-CoV-2 patients from" exact="China" post="[5,6], South Korea [7], and the United States [8]"/>
 <result pre="each country. Clinical characteristics of SARS-CoV-2 patients from China [5,6]," exact="South Korea" post="[7], and the United States [8] have recently been"/>
 <result pre="of SARS-CoV-2 patients from China [5,6], South Korea [7], and" exact="the United States" post="[8] have recently been reported with fever, dry cough,"/>
 <result pre="SARS-CoV-2 patients from China [5,6], South Korea [7], and the" exact="United States" post="[8] have recently been reported with fever, dry cough,"/>
 <result pre="By combining both sequencing and RNA modification data, scientists in" exact="South Korea" post="have identified 41 potential RNA modification sites that could"/>
 <result pre="shortly [59]. Another vaccine that has entered clinical trials in" exact="China" post="has been developed by CanSino Biologics (Tianjin, China), the"/>
 <result pre="COVID-19 treatment with some success [73,74]. However, new data from" exact="China" post="cast doubt on the beneficial effect in seriously ill"/>
 <result pre="RNA-dependent RNA polymerase inhibitor developed by Fujifilm Toyama Chemical in" exact="Japan" post="that is safe and has been effective in other"/>
 <result pre="has been approved by the National Medical Products Administration of" exact="China" post="as the first anti-COVID-19 drug in the country [66]."/>
 <result pre="effect against the SARS-CoV-2 [83]. A multicenter clinical trial in" exact="China" post="has reported efficacy with amelioration of exacerbation of pneumonia"/>
 <result pre="agent during CRS observed in severely ill COVID-19 patients in" exact="China" post="and Italy with promising results [98,99]. COVID-19 patients treated"/>
 <result pre="CRS observed in severely ill COVID-19 patients in China and" exact="Italy" post="with promising results [98,99]. COVID-19 patients treated with Tocilizumab"/>
 <result pre="with promising results [98,99]. COVID-19 patients treated with Tocilizumab in" exact="China" post="showed marked improvement indicating that Tocilizumab potentially could be"/>
 <result pre="administration of tocilizumab in a COVID-19 patient with pneumonia in" exact="Italy" post="showed favorable changes of CT findings within 14 days"/>
 <result pre="SARS-CoV outbreak and informed the response to this pandemic in" exact="Hong Kong," post="Singapore, and Taiwan, for example. Genomic characterization will have"/>
 <result pre="for infectious diseases, flagged unusual infection related activity in Wuhan," exact="China" post="and reported the spread nine days before WHO officially"/>
 <result pre="genome and phylogenetic analysis of two SARS-CoV-2 strains isolated in" exact="Italy" post="in January and February 2020: Additional clues on multiple"/>
</results>
